The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

HIV Infections Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blinded, Dose-Escalation Study Evaluating the Safety and Antiretroviral Activity of HBY 097 Versus HBY 097 Plus AZT in Patients With Asymptomatic or Mildly Symptomatic HIV Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002357
• Other study ID #: 252A
• Secondary ID: HBY097/2001
• Status: Completed
• Phase: Phase 2
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: May 1997
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone.

PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.

Description:

Patients are randomized to receive one of three doses of HBY 097 with or without AZT or AZT alone for 12 weeks (AZT monotherapy arm eliminated per 1/19/96 amendment). All patients at a given dose level of HBY 097 must be enrolled and adequate safety data obtained before escalation in subsequent patients begins. Additional patients are entered at the optimal dose of HBY 097. Patients are evaluated weekly for the first 4 weeks and then every 2 weeks for the next 9 weeks.

PER AMENDMENT: Enrollment to the lowest dose cohort is completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 144
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria

Concurrent Medication:

Allowed:

• Treatment for opportunistic infection that develops on study.

Recommended:

• PCP prophylaxis if CD4 count falls below 200 cells/mm3.

Patients must have:

• HIV infection.

• CD4 count 200 - 500 cells/mm3.

• HIV-1 RNA PCR value of 10000 copies/ml or higher.

• Asymptomatic or mildly symptomatic disease.

• No past or current AIDS-defining event.

• Consent of parent or guardian if less than legal age of consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Endocrine, hepatic, renal, or gastrointestinal disease.

• Cardiovascular conduction disease.

• Concomitant medical illness that may complicate study conduct or interpretation of results.

• Other factors that may interfere with patient compliance.

Concurrent Medication:

Excluded:

• Antiretroviral agents other than study drugs.

• Oral contraceptives.

• Cytotoxic chemotherapy.

• Immunomodulators.

• Antiproliferative agents.

• Corticosteroids.

• Anabolic steroids.

• Estrogens.

• Quinoxaline derivatives.

Concurrent Treatment:

Excluded:

• Radiation therapy.

Patients with the following prior conditions are excluded:

• History of hypersensitivity to quinoxaline derivatives or intolerance to AZT.

• History of cardiovascular conduction disease.

• Prior participation in this study or any study using HBY 097.

• Recent use of a drug that interferes with drug metabolism, absorption, distribution, or excretion.

• History of thyroid disease.

Prior Medication:

Excluded at any time:

Prior non-nucleoside reverse transcriptase inhibitors.

Excluded within 30 days prior to study entry:

• Any antiretroviral therapy.

• Oral contraceptives.

• Immunomodulating agents such as systemic corticosteroids, interleukins, or interferons.

• Cytotoxic chemotherapeutic agents.

• Other investigational drugs.

Excluded within 6 months prior to study entry:

Immunotherapeutic vaccine.

Prior Treatment:

Excluded within 30 days prior to study entry:

• Radiation therapy.

• An experimental device. Current ethanol or illicit drug abuse.

Study Design

Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections

Intervention

Drug:
• HBY 097

• Zidovudine

Locations

Country	Name	City	State
United States	Med College of Georgia	Augusta	Georgia
United States	Houston Clinical Research Network	Houston	Texas
United States	Los Angeles County - USC Med Ctr	Los Angeles	California
United States	New York Univ Med Ctr	New York	New York
United States	Stanford Univ School of Medicine	Stanford	California
United States	Georgetown Univ Med Ctr	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Hoechst Marion Roussel

Country where clinical trial is conducted

United States,